A more recent prospective non-controlled cohort study demonstrated a modest increase in femoral neck BMD and reduction in bone resorption markers CTX in ACPA positive RA patients treated with 2-year tocilizumab. The gene discussed is PRTN3; the disease is rheumatoid arthritis.